Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension

Background African-Americans with hypertension are susceptible to left ventricular hypertrophy (LVH). Serum osteoprotegerin level has been reported to be associated with LVH. We investigated the association of osteoprotegerin with LV mass (LVM) in 898 African-Americans with hypertension (mean age 65 years, 71% women).Methods Osteoprotegerin levels were measured in serum by an immunoassay and log-transformed for analyses. LVM index (LVMi; LVM/height 2.7) was estimated using M-mode echocardiography. Linear regression analyses using generalized estimating equations were used to assess the association of osteoprotegerin with LVMi. Results Serum osteoprotegerin was correlated with LVMi (r = 0.21; P <0.0001), an estimated increase in LVMi of 5.05 (95% confidence interval 2.93, 7.17) g/m 2.7 in the highest compared to the lowest osteoprotegerin quartile. This association remained statistically significant after adjustment for conventional cardiovascular risk factors (age, sex, body mass index (BMI), history of smoking, diabetes, systolic blood pressure (BP), total and high-density lipoprotein cholesterol), estimated renal function, history of myocardial infarction and stroke, lifestyle factors (physical activity score, years of education, amount of alcohol consumption), medications (aspirin, antihypertensives, statins, estrogens), and C-reactive protein (CRP) (P = 0.02). Additionally, osteoprotegerin was correlated with early/atrial (E/A) ratio (r = 0.16; P 0.0001), LV mean wall thickness (r = 0.17; P <0.0001) and relative wall thickness (r = 0.14; P <0.0001) but not ejection fraction (r = 0.04; P = 0.24) or internal end-diastolic dimension (r = 0.02; P = 0.60).ConclusionIn African-Americans with hypertension, a higher serum osteoprotegerin level is weakly but independently associated with a higher LVM.